H-VLPL^TVAEV-OH

Ref. 3D-PP48523

Informação sobre produto

• Nome: H-VLPL^TVAEV-OH

Descrição

Peptide H-VLPL^TVAEV-OH is a Research Peptide with significant interest within the field academic and medical research. This peptide is available for purchase at Cymit Quimica in multiple sizes and with a specification of your choice. Recent citations using H-VLPL^TVAEV-OH include the following: Autologous dendritic cell therapy in mesothelioma patients enhances frequencies of peripheral CD4 T cells expressing HLA-DR, PD-1 or ICOS Y Klaver, PL de Goeje, MEH Kaijen-Lambers - OF SOLID TUMORS , 2019 - core.ac.ukhttps://core.ac.uk/download/pdf/189914944.pdf#page=105 Autologous dendritic cell therapy in mesothelioma patients enhances frequencies of peripheral CD4 T cells expressing HLA-DR, PD-1, or ICOS PL De Goeje, Y Klaver, MEH Kaijen-Lambers - Frontiers in , 2018 - frontiersin.orghttps://www.frontiersin.org/articles/10.3389/fimmu.2018.02034/full Dendritic cells adenovirally-transduced with full-length mesothelin cDNA elicit mesothelin-specific cytotoxicity against pancreatic cancer cell lines in vitro M Miyazawa, M Iwahashi, T Ojima, M Katsuda - Cancer letters, 2011 - Elsevierhttps://www.sciencedirect.com/science/article/pii/S0304383511000863 Autologous dendritic cells pulsed with allogeneic tumor cell lysate in mesothelioma: from mouse to human JGJV Aerts , PL de Goeje, R Cornelissen - Clinical Cancer , 2018 - AACRhttps://aacrjournals.org/clincancerres/article-abstract/24/4/766/81171 Incorporation of porcine adenovirus 4 fiber protein enhances infectivity of adenovirus vector on dendritic cells: implications for immune-mediated cancer therapy I Wilkinson-Ryan, J Kim , S Kim, F Ak, L Dodson - PloS one, 2015 - journals.plos.orghttps://journals.plos.org/plosone/article?id=10.1371/journal.pone.0125851 Allogeneic GM-CSF secreting tumor immunotherapy (GVAX®) alone or in sequence with cyclophosphamide for metastatic pancreatic cancer: a pilot study of D Laheru, E Lutz, J Burke, B Biedrzycki - cancer research: an , 2008 - ncbi.nlm.nih.govhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC2879140/ Allogeneic granulocyte macrophage colony-stimulating factor-secreting tumor immunotherapy alone or in sequence with cyclophosphamide for metastatic pancreatic D Laheru, E Lutz, J Burke, B Biedrzycki, S Solt - Clinical Cancer , 2008 - AACRhttps://aacrjournals.org/clincancerres/article-abstract/14/5/1455/179767 Mesothelin-specific CD8+ T Cell Responses Provide Evidence of In Vivo Cross-Priming by Antigen-Presenting Cells in Vaccinated Pancreatic Cancer Patients AM Thomas, LM Santarsiero, ER Lutz - The Journal of , 2004 - rupress.orghttps://rupress.org/jem/article-abstract/200/3/297/46239

• Marca: Biosynth